# Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Study · id `cardio:ct-nct02638805` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02638805](<https://clinicaltrials.gov/study/NCT02638805>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02638805

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

## Technical summary

Registry record NCT02638805. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2017-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 136 participants (enrolled count; ClinicalTrials.gov record NCT02638805, source copy `cardio:ctgov-nct02638805-2018-11-05`, retrieved 2026-10-26)
- Start date: 2015-12 (registry gives no type) (ClinicalTrials.gov record NCT02638805, source copy `cardio:ctgov-nct02638805-2018-11-05`, retrieved 2026-10-26)
- Primary completion: 2017-10 (actual) (ClinicalTrials.gov record NCT02638805, source copy `cardio:ctgov-nct02638805-2018-11-05`, retrieved 2026-10-26)
- Completion: 2017-10 (actual) (ClinicalTrials.gov record NCT02638805, source copy `cardio:ctgov-nct02638805-2018-11-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02638805, source copy `cardio:ctgov-nct02638805-2018-11-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02638805-2018-11-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): ITCA 650 Osmotic Mini Pump 20/60 mcg/day
- Intervention (Drug): ITCA 650 Osmotic Mini Pump 60 mcg/day
- Intervention (Drug): Metformin
- Intervention (Drug): Liraglutide
- Lead sponsor: Intarcia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Intarcia Therapeutics (`cardio:org-intarcia-therapeutics`)

## Provenance

Content hash: 12f0d8d8b0cb518c868e9b48f144716694917b3d9c78d099a530038489e3675c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
